ARTICLE | Company News
Cellectis S.A, University of Texas MD Anderson Cancer Center deal
September 7, 2015 7:00 AM UTC
MD Anderson and Cellectis partnered to co-develop four allogeneic chimeric antigen receptor T cell therapies from Cellectis to treat non-solid tumors. Cellectis’ candidates are expected to enter clini...